HBsAg in sex workers follows those of the general population where rates of HBsAg carriers have dropped from about 3–6% in the early 1980s to 1–2% over the past years. It seems that partial vaccination of the susceptible population along with safe sex practices over the past years have decreased exposure of sex workers to the virus in our region.

For reasons that are not entirely clear, most epidemiological research and control prevention efforts of sexually transmitted HBV has focused mainly on homosexual men. However, in the present study it was shown that exposure of transsexual sex workers to HBV is not significantly more frequent when compared with female sex workers. Thus, the estimated as highly promiscuous sexual activity of transsexuals seems to not substantially increase their viral exposure. It is possible, that increase in the use of condoms due to an awareness of other STDs such as AIDS has lowered the incidence of hepatitis B in these individuals.

Additionally, infection rate of sex workers, was actually lower on their average age of 15 years of legally sexual work. It is likely, that after their official registration, continuous health education encourage them to take safety precautions and therefore minimizing exposure to the virus. In contrast, the practice of illegal sexual work, which is usually for a time before registering as a sex worker, seems to contribute more in their HBV infection. It seems that screening sex workers for the presence of markers and vaccinating those who are negative will further restrain their exposure to the virus.

A TSAKRIS
Veneral Diseases Clinic, Ministry of Health, Athens, Greece
K P K YKRISAKIS
S CHRYSYSSOU
The West Attica General Hospital, Athens, Greece
G PAPOUTSAKIS
Ministry of Health, Athens, Greece

Correspondence to: Dr A Tsakris, Department of Microbiology, School of Medicine, Aristotelian University of Thessaloniki, 54006 Greece.


Accepted for publication 12 February 1997

---

Genital Chlamydia trachomatis infections in primary care

Ross et al have highlighted the significant proportion of genital Chlamydia trachomatis infections that are diagnosed in practice, and that only a minority of cases (13%) in their district were referred to a genitourinary medicine (GUM) clinic. In the same issue of the BMJ, a postal survey revealed that only 30% of general practitioners in England and Wales would refer a woman with a chlamydial infection to a GUM clinic for contact tracing, follow up, and screening for co-infection. It is a matter of concern that of those who referred, only 30% would prescribe an appropriate antibiotic treatment.

We have reviewed all genital chlamydial infections (diagnosed by enzyme linked immunosorbent assay and confirmed with direct immunofluorescence) in specimens received from hospital and community clinic settings by the Public Health Laboratory Service in Sheffield during the first half of 1996. Of the total of 308 cases with confirmed positive tests, 158 presented for initial screening at the GUM clinic. Of those presenting to other services, 37 were detected in obstetrics/gynaecology attenders, 54 in patients attending family planning services, 73 in patients attending GP surgeries, and six attenders of other services. By cross referencing patient identifiers from positive samples with the GUM clinic register, we found that 64% (90%) of 71 patients attending when gynaecology/family planning clinics (where routine referral to GUM is long established) attended the GUM clinic for management of their infection. This demonstrates that routine GUM involvement in the management of chlamydial infection is both acceptable and achievable in Sheffield.

Moreover, of those patients diagnosed in general practice, 42 (58%) also attended GUM clinics either before or after treatment for further management. Overall, GUM clinics contributed wholly or in part to the management of 268 (87%) of all 308 chlamydia positive patients diagnosed in the city during the study period.

Improved community control of genital chlamydial infections' necessitates not only that diagnostic facilities are widely available, but also that there is close collaboration between GUM clinics and other health services to ensure that comprehensive management is provided for all diagnosed cases. In Sheffield, considerable effort has been made to successfully establish these links. In other locations where such collaboration is not routine, we strongly advocate that general practitioners and other services which screen for chlamydial infections are educated to utilise GUM facilities for partner notification procedures. This will also allow improved epidemiological surveillance of this common sexually transmitted disease within a service which is renowned for maintenance of patient confidentiality.

J ROGSTAD
J KELLOCK
MARK HORTON
Deps of GUM, Royal Hallamshire Hospital, Broomhead Road, Sheffield S10 2TF
G KUDELSIA
PHLS, Northern General Hospital, Harris Road, Sheffield S5 7AU


Accepted for publication 12 February 1997

---

Failure of trimethoprim in the treatment of donovanosis

Antibiotics for the treatment of donovanosis include tetracyclines, chloramphenicol, co-trimoxazole, and ceftriaxone. Co-trimoxazole has been used with considerable success. In India and South Africa the favoured regimen is two tablets of co-trimoxazole twice daily for at least 10 days, and good compliance and results with this dosage have been reported. However, to date at least four cases of failure of co-trimoxazole in the treatment of donovanosis have been reported.

Doctors in the UK have been urged to use trimethoprim alone rather than co-trimoxazole when there is no clear advantage with the latter. This reflects concern about the serious toxicity associated with sulphonamide use, particularly Stevens-Johnson syndrome, blood dyscrasias, and hepatotoxicity. When first introduced, the combination of sulphonamides and trimethoprim was shown in vitro to be synergistic, but studies have shown trimethoprim to be just as effective as co-trimoxazole in the treatment of chest and urinary tract infections. The use of the combination has not reduced the incidence of resistance to trimethoprim. With the exception of two reports, sulphonamides have not been found to be useful in the treatment of donovanosis other than as a component of co-trimoxazole; with this in mind, it seems prudent to prescribe trimethoprim instead. We are not aware of any trials of the use of trimethoprim in the treatment of donovanosis. Here we describe failure of trimethoprim in treatment of a case of donovanosis.

Our patient, a Jamaican man, presented with a penile ulcer of 8 weeks' duration (fig). There was no dysuria or urethral discharge. He had had impotence for 3 months previously in Jamaica. Initial diagnostic tests were negative for chlamydia, gonorrhoea, and treponemes. Repeated dark-ground microscopy examinations on 3 subsequent occasions showed no pathogens. And culture for Haemophilus ducreyi was also negative. Our patient was treated initially with trimethoprim, 200 mg twice daily. After 3 weeks there was no improvement in the lesion. A punch biopsy and culture and a subsequent histological section for treponemal infection were negative, a biopsy was performed, which showed...
confirmed the diagnosis of donovanosis. A 6 week course of doxycycline 100 mg twice daily was commenced, and the patient made a full recovery.

In view of the increased transmissibility of HIV in association with ulcerating genital infections, an effective and acceptable oral agent is required for the treatment of donovanosis. Few well designed controlled trials have addressed this problem. Effective treatment and prevention of ulcerating genital disease is important in the control of the spread of HIV. Clinicians investigating patients from tropical countries should be aware that trimethoprim and co-trimoxazole do not always eradicate donovanosis.

KARL BIRTHSTILE
JAMES GREG
Department of Medical Microbiology,
St George's Hospital Medical School,
London SW17 0RE

accepted by guest.

Perforation of hard palate in lues maligna associated with HIV infection

Unusual oral and skin manifestations of infectious diseases may be observed in patients with HIV infection.1,2 These are quite often a challenge to the clinician. Destructive bone diseases such as osteitis and osteomyelitis are well known complications of congenital and tertiary syphilis; they are rare complications of early acquired syphilis.3 We report a case of perforation of hard palate in lues maligna associated with HIV infection.

A 30 year old promiscuous male presented with a solitary genital ulcer and recurrent erethymatous nodules and ulcers over the limbs (fig 1) and trunk for the past 5 months, associated with joint pains, swelling over the limbs, fever, headache, myalgia, and epistaxis. On further examination he had inguinal and epitrochlear lymphadenopathy. Oral examination revealed a mucosal patch and perforation over the hard palate (fig 2). Dark ground microscopy from the genital ulcer revealed several motile spirochaetes. VDRL was reactive in 1:128, TPPA and HIV (ELISA) were positive. Blood examination revealed normocytic normochromic anaemia with increased rouleaux formation, raised ESR (>150 mm in the first hour). Liver function tests, antinuclear antibody (ANA), and double stranded DNA were within normal limits. The patient refused to undergo skin biopsy and lumbar puncture. In view of the clinical features, dark ground examination, and serological findings secondary spirochaetes (lues maligna) was considered. He was treated with procaine penicillin 24 units for 2 weeks. On follow up his skin lesions had healed.

The case is interesting because of early palatal perforation following lues maligna in this HIV patient. A review of the literature of the past 20 years revealed that of 1800 patients with early syphilis, less than 0·2% had evidence of periostitis, and there were no reports of destructive bone lesions.4 A recent review of bone and joint disease in association with HIV infection does not report syphilis related bone disease.5 Cases of HIV associated lues maligna with widespread, atypical ulcerations of the oral mucosa and skin have been reported.6,7 We postulate that destructive cell mediated immunity might have facilitated the rapid dissemination of spirochaetes invading bones and joints resulting in bone destruction. Numerous spirochaetes observed in bone biopsy speci men suggesting the aggressiveness of syphilis in a patient with concurrent HIV infection has been documented earlier.

C BALACHANDRAN
L SABITA
G R KANTHRAJ
Department of Skin & STD,
Kasturba Medical College,
Mangaluru—576 119,
Karnataka, India

accepted for publication 12 February 1997


Sharing prescribing of continuous aciclovir treatment: effects of a new policy and general practitioner responses

Recent guidelines on the care of patients with genital herpes1 include reference to improved communication between local genitourinary medicine clinics and general practitioners. This reinforces anecdotal reports that in some areas of the UK general practitioners and genitourinary medicine clinics were satisfactorily collaborating in the management of patients requesting continuous treatment with aciclovir.

In early 1996 the national reduction in HIV funding by 7-7% and the lack of designated additional funding for new antiviral drugs has resulted in extreme pressure on the drug budget within the directorate of HIV/GU medicine at the Chelsea and Westminster Hospital and prompted us to examine ways of extending collaboration with general practitioners with the secondary gain of achieving an overall reduction in our drugs budget. After discussion within the unit and with purchasers we attempted to reduce our personal deficit by restricting hospital prescribed therapies to treatments for HIV infection, and acute and new presentations of STDs. With the intention of preserving patient choice concerning confidentiality, however, we asked for our patients' specific consent to write to their general practitioners to request them to share responsibilities in the prescribing of continuous aciclovir for the prevention of recurrent genital herpes. This policy took effect from April 1996, and during the following 5 months we approached 71 patients who were receiving regular prescriptions for continuous aciclovir to prevent recurrences of culture proved genital herpes from the genitourinary medicine clinic. Eight patients refused to have their herpes diagnosis and prescription needs disclosed to their general practitioners,